Phase I--II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma.

Abstract

Methyl-GAG, a polyamine synthesis inhibitor, was prospectively evaluated in the treatment of advanced renal adenocarcinoma. Twenty-five patients with measurable disease received methyl-GAG weekly at a starting dose of 500 mg/m2 iv, with dose escalation by 50 mg/m2/week (maximum dose, 825). All 25 patients are evaluable for response. Four of these patients (16%) achieved responses including three partial responses and one complete response, with a median duration of 9 weeks (range, 4--15). Nine patients (36%) remained stable and 12 (48%) had progressive disease. In the four responders, regression of disease occurred within the first 4 weeks of therapy. Toxic effects were generally mild and included nausea or vomiting (68%), myalgia (44%), mucositis (40%), neuralgia (40%), weight loss (32%), diarrhea (24%), skin rash (8%), leukopenia (8%), and genital ulcers (4%). We conclude that methyl-GAG has clear, albeit limited, activity against renal adenocarcinoma.

• Authors: R F Todd 3rd, M B Garnick, G P Canellos, J P Richie, R F Gittes, R J Mayer, A T Skarin
• Journal: Cancer treatment reports (Cancer Treat Rep) 1981 Jan-Feb Vol. 65 Issue 1-2 Pg. 17-20 ISSN: 0361-5960 [Print] United States
• PMID: 7226167 (Publication Type: Journal Article)

Chemical References

• Guanidines
• Mitoguazone

Topics

• Adenocarcinoma (drug therapy)
• Adolescent
• Adult
• Aged
• Drug Administration Schedule
• Drug Evaluation
• Female
• Guanidines (therapeutic use)
• Humans
• Kidney Neoplasms (drug therapy)
• Male
• Middle Aged
• Mitoguazone (administration & dosage, adverse effects, therapeutic use)
• Neoplasm Metastasis
• Prospective Studies